Navigation Links
Baxter Announces Licensing Agreement for Innocoll's Gentamicin Surgical Implant in the United States
Date:8/25/2008

The antibiotic surgical product may reduce incidence of surgical site

infections and reduce post-operative cost and complications

DEERFIELD, Ill. and ASHBURN, Va., Aug. 25 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation today announced a licensing agreement with Innocoll Pharmaceuticals Ltd, a division of Innocoll, Inc., granting Baxter exclusive rights to market and distribute the company's gentamicin surgical implant in the United States. The gentamicin surgical implant will be the first and only biodegradable, leave-behind antibiotic surgical sponge used as an adjunct (add-on) therapy for prevention and treatment of surgical site infections (SSIs) in the United States. This agreement is expected to add to Baxter's biosurgical portfolio by giving surgeons an innovative option to help reduce risk of post-operative complications of SSIs during surgery.

The collagen-based implant is saturated with a high concentration of an antibiotic, gentamicin, designed to deliver the antibiotic directly to the target tissue while maintaining low levels of the drug in order to potentially reduce infection during and after surgery. The gentamicin surgical implant is fully biodegradable and can be left in the body after surgery. According to the Centers for Disease Control and Prevention, SSIs remain an ongoing problem for surgeons and are a burden on patients and the healthcare system, affecting more that 500,000 patients a year in the United States.

The product was developed using Innocoll's proprietary, collagen-based drug delivery technology, CollaRx, and is indicated outside of the United States as an adjunct to systemic antibiotic therapy for the treatment of localized, deep tissue infections and the prevention of SSIs in both hard and soft tissues.

The implant is approved in 49 countries spanning Europe, Latin America, the Middle East, Africa and Asia. It is currently in two Phase III clinical trials in the United States to
'/>"/>

SOURCE Baxter Healthcare Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Baxter Declares Quarterly Dividend
2. Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
3. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
4. Baxters Board of Directors Declares Quarterly Dividend
5. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
6. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals
7. Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
8. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
9. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
10. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
11. Baxter Declares Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2013 was a banner year of ... They saw continued independent research led by the team ... a $1 million grant from the Susanne Marcus Collins ... a peer reviewed journal, Amy Grant highlighted Brainwave Optimization® ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up their ... of them wrote: "Take better care of my furry companion." Nowadays ... clothes and top-brand carrying cases to take the little canine or ... also feel compelled to buy some pricey toys at the pet ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... made as distribution channel reorders,continue, FREDERICK, ... maker of ActiPatch(R) Therapy, the drug free ... delivering continuous pulse,therapy that revolutionizes the way ... distribution penetration into the Canadian market.,ActiPatch Therapy ...
... Consultancy for Emerging Chinese Companies, HAIKOU CITY, ... Inc. ("China Pharma") (OTC Bulletin Board: CPHI),which develops, ... China, today announced the appointment of,The Ruth Group ... Zhilin Li, President and CEO of China Pharma ...
... BURLINGAME, Calif., Oct. 21 Sensorin, which ... measurement,platform for bioprocess applications, today announced the ... Use of proceeds from the financing includes,product ... proprietary pH,sensing system. Terms of the financing ...
Cached Biology Technology:BioElectronics Announces Significant Progress in Canadian and International Distribution 2China Pharma Holdings, Inc. Appoints The Ruth Group 2China Pharma Holdings, Inc. Appoints The Ruth Group 3Sensorin Raises Equity Financing to Launch Novel Industrial Sensing Venture 2
(Date:7/9/2014)... 2014) Emerging fungal pathogens pose a greater ... causing population declines of amphibians, bats, corals, bees ... South Florida published in the prestigious journal ... or immunological resistance to a deadly chytrid fungus ... "Acquired resistance is important because it is the ...
(Date:7/9/2014)... critically ill children with traumatic injuries have identified ... likely to develop a hospital-acquired infection. The study, ... published online in June in the journal ... that could lead to the clinical implementation of ... or reverse immune system damage following critical illness ...
(Date:7/9/2014)... about the prevalence of antibiotic-resistant illness, Case Western ... to disabling disease: blocking bacteria,s access to iron ... bacterial siderophore, a small molecule, captures iron from ... as well as how the body launches ... findings appear in a recent edition of ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3Bacteria hijack plentiful iron supply source to flourish 2
... engineers, led by the University of Alberta and the ... $3.39 million, three-year study to assess the potential effects ... "Nanotechnology is a very new and quickly developing field. ... solid scientific data upon which to base their regulatory ...
... In a discovery that rebuffs conventional scientific thinking, ... a novel way to block the activity of the ... found in children and young adults. In the ... , they report discovering and successfully testing a small ...
... 2009 Researchers at Ben-Gurion University of the Negev (BGU) ... may increase the possibility for diseases, including cancer., The findings ... Research ., The team of researchers from BGU,s National Institute ... for mutations in the genome of the mitochondria, a part ...
Cached Biology News:Canadian researchers set to study impact of nanomaterials on aquatic ecosystems 2GUMC discovery highlights new direction for drug discovery 2GUMC discovery highlights new direction for drug discovery 3Ben-Gurion U. researchers reveal connection between cancer and human evolution 2
propidium iodide *1.0 mg/mL solution in water*...
1 unit is sufficient for 1 caspase activity assay....
Applications: (+) Immunocytochemistry and immunohistochemistry...
Anti-Rat KAPPA/LAMBDA:HRP, Clone MARK-1/MARL-15, Monoclonal Antibody...
Biology Products: